The reduction of both Aβ and βCTF/sAPPβ through dyn1 knockdown may be a better therapeutic strategy compared to those targeting γ-secretase, given that recent data suggest β- but not γ-secretase-mediated proteolysis of APP causes synaptic and memory deficits in AD [34]. This evidence concerns the gene APP and Alzheimer disease.